肺癌、关节炎和痛风:来自ASCO和EULAR的报告

Future Prescriber Pub Date : 2009-08-13 DOI:10.1002/fps.53

Sue Lyon

{"title":"肺癌、关节炎和痛风:来自ASCO和EULAR的报告","authors":"Sue Lyon","doi":"10.1002/fps.53","DOIUrl":null,"url":null,"abstract":"The second most common cancer diagnosed in the UK, lung cancer, is also the most deadly. Over twothirds of patients present with advanced disease, and at present only 7% survive for at least five years after diagnosis.1 New hope is offered by studies presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), held on 28 May–2 June in Orlando, USA Copyright © 2009 John Wiley & Sons, Ltd.","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 3","pages":"24-25"},"PeriodicalIF":0.0000,"publicationDate":"2009-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.53","citationCount":"0","resultStr":"{\"title\":\"Lung cancer, arthritis and gout: reports from ASCO and EULAR\",\"authors\":\"Sue Lyon\",\"doi\":\"10.1002/fps.53\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The second most common cancer diagnosed in the UK, lung cancer, is also the most deadly. Over twothirds of patients present with advanced disease, and at present only 7% survive for at least five years after diagnosis.1 New hope is offered by studies presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), held on 28 May–2 June in Orlando, USA Copyright © 2009 John Wiley & Sons, Ltd.\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"10 3\",\"pages\":\"24-25\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.53\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.53\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.53","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Lung cancer, arthritis and gout: reports from ASCO and EULAR

The second most common cancer diagnosed in the UK, lung cancer, is also the most deadly. Over twothirds of patients present with advanced disease, and at present only 7% survive for at least five years after diagnosis.¹ New hope is offered by studies presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), held on 28 May–2 June in Orlando, USA Copyright © 2009 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量